Evaxion Revolutionizes Immunology with Groundbreaking Advances
Evaxion, a leading biotech company, has made significant strides in the field of immunology, showcasing its innovative AI-Immunology platform's capabilities. According to their recent Q4 2025 conference call transcript, the company reported tremendous progress across all core pillars.
One notable achievement was the collaboration with MSD on infectious disease vaccines, resulting in Merck exercising its option over the EVX-B3 program candidate. This represents a significant milestone as it is the first vaccine candidate identified and validated through an AI discovery platform to be licensed by a major pharmaceutical company. Although MSD chose not to exercise its option over the EVX-B2 candidate for gonorrhea, Evaxion remains optimistic about this program's prospects.
Another key highlight was the entry into a collaboration with The Gates Foundation on designing a new polio vaccine and seeing significant interest in their platform and pipeline programs from various parties. In R&D, the company presented positive 2-year phase II data at ESMO for its EVX-01 program, showcasing a personalized neoantigen-directed cancer vaccine's efficacy in advanced melanoma patients.
Additionally, Evaxion's AI-Immunology platform was recognized by the Galien Foundation for AI advances in human health. The company has also successfully increased its capital influx through financing, business development, and the use of their ATM, providing a cash runway to H2 2027. This funding will enable Evaxion to continue driving innovation and progress.
The biotech's pipeline boasts a range of novel product-focused assets, including clinically validated cancer vaccine candidates, DNA and RNA platforms, and preclinical infectious disease vaccine candidates targeting challenging targets. The company is also exploring the application of its AI-Immunology platform within the autoimmune field, given its direct applicability to immune mechanisms in disease.
The successes reported by Evaxion demonstrate the potential of their AI-Immunology platform to revolutionize immunology and address significant medical needs. As the company continues to innovate and expand its capabilities, it is likely to make even more groundbreaking advancements in the future."
